The Replimune Group, Inc. (Nasdaq: REPL) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a clinical stage biotechnology issuer. Replimune, founded in 2015 and headquartered in Woburn, Massachusetts, develops HSV‑1‑based oncolytic immunotherapies through its proprietary RPx platform, with lead programs such as RP1 (vusolimogene oderparepvec) and RP2.
Through this page, users can review Replimune’s current reports on Form 8‑K, which frequently highlight material events including FDA interactions, clinical milestones and financial updates. Recent 8‑K filings have described the FDA’s Complete Response Letter for the RP1 BLA in advanced melanoma, completion of a Type A meeting with the agency, acceptance of a BLA resubmission with a defined PDUFA date, quarterly financial results, and outcomes of the company’s annual meeting of stockholders.
In addition to 8‑Ks, investors can reference Replimune’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (accessible via the SEC’s EDGAR system) for detailed information on the company’s clinical programs, risk factors, financial condition and cash runway assumptions. The DEF 14A proxy statement provides insight into governance, board structure, executive compensation and matters submitted to shareholder vote, such as director elections and incentive plan amendments.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, helping users quickly understand topics like trial design disclosures, regulatory status updates for RP1 and RP2, and the implications of shareholder meeting results. Real‑time updates from EDGAR mean that new Replimune filings, including future 10‑K, 10‑Q, 8‑K and proxy materials, are made available promptly.
For those monitoring insider and equity‑related activity, Replimune’s filings also describe equity incentive plans and inducement grants under Nasdaq Listing Rule 5635(c)(4). Form 4 insider transaction reports, when filed, can be viewed alongside these materials to provide additional context on equity ownership and changes over time.
Replimune Group amended a Schedule 13G/A to report that T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune common stock, representing 0.2% of the class. The filing states T. Rowe Price has sole voting power over 152,716 shares and sole dispositive power over 157,965 shares. The filer affirms this ownership disclosure while also denying beneficial ownership in a boilerplate statement.
Replimune Group, Inc. reported that the U.S. Food and Drug Administration issued a second Complete Response Letter for its Biologics License Application for RP1 in combination with nivolumab for treating advanced melanoma.
The company states that, without timely accelerated approval, continued development of RP1 will not be viable and it will eliminate jobs, including substantially scaling back its U.S.-based manufacturing operations. This follows data from the IGNYTE trial where patients with advanced melanoma progressing on prior anti-PD-1 therapy receiving RP1 plus nivolumab showed a 34% response rate with a median response duration of 24.8 months and a favorable safety profile.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Replimune Group, Inc. disclosed a compensation-related grant of 44,500 non-qualified stock options to director Michael Goller, a full-time employee of Baker Bros. Advisors LP. The options are exercisable into Common Stock at a $7.61 strike price, vest on April 1, 2027 subject to continued board service or a change in control, and expire on April 1, 2036. Baker Bros. Advisors has voting and dispositive power over these options, while affiliated Baker Bros. funds and principals hold only an indirect pecuniary interest and expressly disclaim beneficial ownership beyond that interest. The same 44,500-option grant is reported for each fund that shares this indirect interest.
Replimune Group, Inc. disclosed that Chief Commercial Officer Christopher Sarchi received new equity awards as part of his compensation. He was granted employee stock options for 75,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and monthly thereafter until fully vested. He also received 50,000 restricted stock units (RSUs), each representing one share of common stock, vesting 25% on May 15, 2027 and then in three approximately equal annual installments through May 15, 2030, subject to continued service. Following these awards, he directly holds 201,588 shares of common stock. These are compensation grants, not open‑market purchases or sales.
Replimune Group director Philip Astley-Sparke reported compensation-related equity awards. He received a stock option for 75,000 shares of common stock at an exercise price of 7.6100 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
He also received 50,000 shares of common stock issuable upon settlement of restricted stock units, with 25% vesting on May 15, 2027 and the remainder in three approximately equal annual installments through May 15, 2030, subject to continuous service. Following the grant, he directly holds 1,430,071 common shares. These are grants/awards, not open-market purchases or sales.
Replimune Group, Inc. director Christy J. Oliger received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing footnote, all shares underlying this option vest on April 1, 2027. Following this grant, Oliger holds stock options for 44,500 shares directly, reflecting a compensation-related award rather than an open-market trade.
Replimune Group, Inc. reported that Chief Medical Officer Konstantinos Xynos received new equity awards as part of his compensation. He was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty‑five percent of these option shares will vest on April 1, 2027, with the remainder vesting in 36 roughly equal monthly installments.
He also acquired 50,000 shares of common stock through restricted stock units (RSUs). Each RSU represents one share of common stock, with 25% vesting on May 15, 2027 and the rest vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following these grants, he directly owns 249,685 common shares.
Replimune Group, Inc. director Madhavan Balachandran received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the footnote, all underlying shares vest on April 1, 2027.
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.
Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.